RDIF files application with EMA for Sputnik V coronavirus vaccine approval
MOSCOW. Feb 9 (Interfax) - The Russian Direct Investment Fund (RDIF) has filed an application with the European Medicines Agency (EMA) to obtain approval for the use of the Sputnik V coronavirus vaccine in the European Union.
"RDIF filed for Sputnik V registration in the EU on January 29, 2021 and started submitting the information to EMA for the rolling review," the RDIF said in a statement on Tuesday.
The RDIF has received official confirmation from the EMA that its application has been accepted. "It is up to EMA to determine the speed of the review process," it said.
The RDIF applied for the EMA's Scientific Review of Sputnik V on October 22, 2020, and teams from the RDIF, the Russian research institute that developed Sputnik V, and the EMA held the vaccine's Scientific Review on January 19, it said.
The media reported earlier that the EMA was expecting an application from the RDIF for the vaccine's approval.